The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for TRN-257, a controlled-release, low-sodium oxybate product, for the treatment of c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback